Mary Ellen Frustaci

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

William J. Sandborn, Geert D’Haens, Walter Reinisch et al. · Gastroenterology · 2022 · 188 citations · Full text

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Priscilla Hollander, Harold Bays, Julio Rosenstock et al. · Diabetes Care · 2017 · 106 citations

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist <scp>JNJ</scp>‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study

Maria Alba, Jaqueline Yee, Mary Ellen Frustaci et al. · Clinical Obesity · 2021 · 87 citations

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 61 citations

Urology, Moxibustion, Gastroenterology +6

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist <scp>JNJ</scp>‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

Nicholas A. Di Prospero, Jaqueline Yee, Mary Ellen Frustaci et al. · Clinical Obesity · 2021 · 54 citations